(NASDAQ: CRVO) Cervomed's forecast annual revenue growth rate of 21.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Cervomed's revenue in 2024 is $7,144,872.On average, 1 Wall Street analysts forecast CRVO's revenue for 2024 to be $49,363,832, with the lowest CRVO revenue forecast at $49,363,832, and the highest CRVO revenue forecast at $49,363,832.
In 2025, CRVO is forecast to generate $36,405,826 in revenue, with the lowest revenue forecast at $36,405,826 and the highest revenue forecast at $36,405,826.